New sedation cocktail aims to protect elderly patients during routine scopes

NCT ID NCT07707258

First seen Jul 16, 2026 · Last updated Jul 22, 2026 · Updated 3 times

Summary

This trial investigates whether combining two drugs, remimazolam and oliceridine, can provide safer sedation for elderly patients (ages 65-80) undergoing painless gastrointestinal endoscopy. The goal is to maintain stable breathing and blood pressure while reducing risks like low oxygen levels and cognitive changes after the procedure. Participants will be randomly assigned to receive either the new combination or the standard sedative sufentanil, and their vital signs will be closely monitored.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
remimazolam combined with oliceridine
What this could lead to
If successful, this could lead to a safer sedation option for elderly patients undergoing gastrointestinal endoscopy, with fewer breathing and blood pressure complications.
What could go wrong
This is a small, early-stage trial, so results may not apply to all elderly patients. The combination might still cause side effects like low oxygen or blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL ENDOSCOPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hypoxia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shanghai Baoshan District Dachang Hospital (Renji Hospital Baoshan Branch)

    RECRUITING

    Shanghai, Shanghai Municipality, 200444, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.